Navigation Links
Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
Date:8/19/2007

including cancer cells that are no longer responsive to normal growth control mechanisms. Non- proliferating cells are relatively insensitive to Vidaza. Vidaza was approved for IV administration in January 2007.

About Epigenetics

Vidaza is the first of a new class of anti-cancer compounds known as epigenetic therapies. Epigenetics refers to changes in the regulation of gene expression, and DNA methylation and histone deacetylation are two of the more studied epigenetic regulators of gene expression. Epigenetic changes can silence gene expression and, unlike DNA mutations, may be reversed by targeting the mechanisms involved. The silencing of key cell cycle control genes and tumor suppressor genes through these two mechanisms of epigenetic regulation has been demonstrated in vitro and in vivo in hematological malignancies and in solid tumors. These key growth control genes can be re- expressed in cancer cells when DNA hypermethylation is reversed by Vidaza. The epigenetic approach to cancer therapy is that rather than using molecules that kill both normal, and tumor cells, the silenced genes are reactivated through targeted epigenetic therapy, re-establishing the cancer cell's natural mechanisms to control abnormal growth.

About MDS

Myelodysplastic syndromes, or MDS, are a group of diseases in which the bone marrow does not function normally, resulting in the production of malformed or immature blood cells. MDS affects approximately 40,000-50,000 people in the United States and 75,000-85,000 patients in Europe. The majority of patients with higher-risk MDS eventually experience bone marrow failure. Up to 50 percent of MDS patients succumb to complications, such as infection or bleeding, before progressing to acute myeloid leukemia (AML). MDS patients have a median survival of four months to five years depending on risk stratification. Higher-risk patients have a median survival of five to 14 months. Alleviation of disease-related complications
'/>"/>

SOURCE Pharmion Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
2. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
3. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
4. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
5. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
6. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
7. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
8. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
9. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  Growth of the U.S. nonprescription ... bring former prescription users to the OTC market. Due ... forecasts robust Rx-to-OTC switch activity over the next five ... with many new brands entering the market into existing ... next five years (even those with low to moderate ...
(Date:7/30/2015)... MIAMI , July 30, 2015   ... latest update to UNI®, the world,s first operating ... simulators, is now available exclusively to Gaumard users. ... for recently launched Newborn Tory™ S2200, as well ... and monitoring of clinical measures such as EtCO ...
(Date:7/30/2015)... , July 30, 2015 What ... ? Which areas are going to grow at the ... you potential revenues to 2025, assessing data, trends, opportunities ... provides 176 tables, charts, and graphs. Discover the ... market prospects. Our new study lets you assess forecasted ...
Breaking Medicine Technology:Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 2Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 3Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 5Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 6
(Date:7/30/2015)... ... July 30, 2015 , ... 24/7 Care At Home, a ... San Bernardino, recently announced that the Centers for Medicare and Medicaid (CMS) have awarded ... health care providers. 24/7 Care At Home’s agency is one of three top Orange ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... expand, as the company and UCLA’s Jonsson Comprehensive Cancer Center (JCCC) ... today. With the new collaboration, OncLive’s editorial and marketing groups will help spread ...
(Date:7/30/2015)... ... July 30, 2015 , ... Glidewell Laboratories, industry-leading provider of ... magazine, its multimedia publication focused on implant dentistry, is now available in print ... 6, Issue 2, as well as past issues of the dental laboratory’s quarterly ...
(Date:7/30/2015)... ... , ... On July 23rd Clay Today Online reported the state ... large prison system, which has amassed largely enough throughout the years. Florida is the ... President Obama’s recent reduction of non violent drug offender’s prison sentences, Florida is beginning ...
(Date:7/30/2015)... ... ... Gummy smile surgeon, Dr. Alex Farnoosh, now offers comprehensive treatment ... the patented gum depigmentation treatmet. Dr. Farnoosh is a renowned dentist with decades of ... the world. , “Like treatment of any other disease or condition, making the correct ...
Breaking Medicine News(10 mins):Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 4Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2
... WALTHAM, Mass., May 28 According to Millennium Research ... Economic Quarterly (EQ), the health care and ... of the economy; while this may be true, however, ... the impact from the downturn, although not all segments ...
... -- China Sky One Medical, Inc. ("China Sky One ... a leading fully integrated pharmaceutical company in the People,s ... Cooleman, Flemish economic representative for the North of the ... Company ("TDR"), a wholly-owned subsidiary of China Sky One, ...
... New York personal injury lawyer David Perecman questions the presence of an unfenced ... ... A girl falls 30 feet through a skylight and New York personal ... 30-foot drop has the potential to cause far more severe injuries then only ...
... ... From Constipation(1): From Connecticut to California, the United ... While it might not be surprising to learn ... the results of a new survey show just how ... In fact, while more than one-half of adults surveyed ...
... Scar Product to Receive AAD SEAL OF RECOGNITION(R)GREENSBORO, ... Dermatology (AAD) has honored Merz Pharmaceuticals with its ... sun-protection benefit. The AAD SEAL OF RECOGNITION(R) recognizes ... review of independent testing results by an independent ...
... LEHIGH VALLEY, Pa., May 28 Air Products (NYSE: ... and Chief Executive Officer John E. McGlade will be ... New York on Thursday, June 4, 2009, at 8:00 ... be available on Air Products, Investor Relations web site ...
Cached Medicine News:Health News:Although the Health Care Market is Recession-Resistant, It Is Not Recession-Immune, According to Millennium Research Group's Medtech Economic Quarterly Publication 2Health News:China Sky One Medical, Inc. Welcomes Commercial Counselor from Belgium; Looks for Business Alliance with European Companies 2Health News:China Sky One Medical, Inc. Welcomes Commercial Counselor from Belgium; Looks for Business Alliance with European Companies 3Health News:Girl Falls 30 feet through a Skylight and New York Personal Injury Lawyer David Perecman is not Falling for Excuses 2Health News:Guess What Most Americans Don't Want to Talk About (Hint: It's Not Sex!) 2Health News:Guess What Most Americans Don't Want to Talk About (Hint: It's Not Sex!) 3Health News:Guess What Most Americans Don't Want to Talk About (Hint: It's Not Sex!) 4Health News:American Academy of Dermatology Recognizes Merz Pharmaceuticals 2Health News:American Academy of Dermatology Recognizes Merz Pharmaceuticals 3Health News:American Academy of Dermatology Recognizes Merz Pharmaceuticals 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: